DNAY earnings call for the period ending June 30, 2022.
SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today reported...
SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced...
BioXpâ„¢ system and RapidAMPâ„¢ cell-free DNA kit rapidly accelerate antibody discovery pipelines by addressing critical bottlenecks associated with lead...
DNAY earnings call for the period ending March 31, 2022.
SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced...
BioXpâ„¢ system and RapidAMPâ„¢ cell-free DNA kit allow scientists to synthesize, clone, and amplify antibody-variable regions based on a digital sequence...
Proof-of-concept studies go beyond typical DNA data storage projects to ensure high-fidelity data recovery within an automated synthetic biology workflow...
SOLA approach has the potential to be more accurate, scalable, and cost-effective compared to traditional chemical synthesis and alternative enzymatic...
DNAY earnings call for the period ending December 31, 2021.